Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. - Wikidata - wikimedia - TriplyDB

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

http://www.wikidata.org/entity/Q44929883

about

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β Targeted DNA mutagenesis for the cure of chronic viral infections The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection Prophylaxis against Recurrence in Liver Transplantation Patients with Hepatitis B Virus: What is New?HBV induced HCC: major risk factors from genetic to molecular level Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis Current and future antiviral drug therapies of hepatitis B chronic infection Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas The Role of cccDNA in HBV Maintenance.Detection of HBV Covalently Closed Circular DNA Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.Occult hepatitis B virus and hepatocellular carcinoma Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner.Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity Development of cell cultures that express hepatitis B virus to high levels and accumulate cccDNA.The Role of Interferon in Hepatitis B Therapy.Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China.Antiviral treatment of chronic hepatitis B virus (HBV) infections Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.Strategies to eliminate HBV infection.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact Hepatitis B virus and hepatitis C virus dual infection.Current status of antiviral therapy for hepatitis B Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs.Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.

P2860

Q21128797-BBACBDF4-8D46-4698-AD2B-1560D640322F Q24338960-85BDD9DA-1B50-419F-B186-A2A53ABF0F1C Q24620150-FDB169AA-A85D-4725-A846-C67074905B9D Q26771469-311666C2-0C8D-4735-A72A-C159868D94D0 Q26781880-1BBB2193-8E22-42DA-A918-FCA9715482E1 Q26825274-44CC4486-2154-4AB0-96F6-689AF1273E5D Q27324340-96FE3FB5-5EF6-49F2-9C16-14D986F4378A Q27487167-9A03CC73-401A-432E-8AE2-CBE5D241BC2D Q27488200-7A46D12F-C372-4810-A9F8-3B4C6AA4DE47 Q28084820-E0D4BB2C-076C-481C-998B-EE9DBB154A83 Q28087526-745A980C-446E-4402-9FAE-A09A045BEED6 Q28484005-4F9E1D11-5636-4153-AC6F-80B4983B10DE Q28485228-132A40D2-9B9D-44D8-80DD-71F7C9FE6D48 Q28552967-EB83CBDC-7162-4478-BAE7-C53E32BD4315 Q28649881-C3ED8105-1412-483C-BA70-68FC1537224D Q32182914-37D33EE5-FE90-464D-8024-934844B4D6B2 Q32183310-372C2377-F1EA-4C04-9D2B-A0BEE519B8BF Q33349693-9E62D0A4-585F-4A36-9C93-C238B170591A Q33661018-A067265A-0BA3-49D0-9823-C772A7A80724 Q33686965-FEF35361-0816-4C85-A44C-BD2EBC679CA3 Q33695646-9116D0E8-F1CB-4D73-B435-7FFAEF7AB5B0 Q33721394-4BB9CAAA-2A21-412C-8563-DD0B0001828E Q33755065-5ECB6675-06AF-4575-9CF4-DC8E5A6E833E Q33812210-C9B663C7-C21D-4633-8D58-A04D1DF2BF2F Q33819124-8B3239D2-3F3E-4ED7-8181-2BF4C006C35E Q33918392-E44ACA4F-27A1-4D15-8934-AEC76F858EDE Q33981411-4B122058-0204-444C-8CA3-6B4AA0B4A9C4 Q34091587-F056FE4A-E1F0-48C2-A802-51CC6F9C6101 Q34154958-7E753965-721E-4A61-9B54-A1BEBCD90B74 Q34189348-41D2D9BB-82EF-4652-803F-D0DEA53D9401 Q34206628-B4BDB006-9C86-45E7-A955-A4E1D5EC9878 Q34223779-21710E65-CF78-46D5-A9DD-64D91BA56EE6 Q34289969-330DF9D1-E053-474C-ADFE-7E442DEA340D Q34308129-4D89F1E0-11DE-4C0B-A128-243D926B6C0D Q34335676-CAC2AFD4-CB99-4748-9C5A-13D754829C0B Q34387363-5595980D-C081-43CC-AF6E-D90692BFFE53 Q34404975-497996F5-B49F-49EC-8A68-2F71162CA41E Q34408879-40F18333-FF19-4665-9B66-9B1D5CADC17B Q34456173-9D59C8A4-8E09-4551-85B6-B80FC99106BA Q34457758-33D2C983-74B2-4683-9581-40E13D9EC493

P2860

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

http://www.wikidata.org/entity/Q44929883

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@en

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@nl

type

label

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@en

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@nl

prefLabel

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@en

Persistence of cccDNA during t ...... ng adefovir dipivoxil therapy.

@nl

P1433

Q44929883-4484B638-D428-4FBF-B39E-AAAFF778E04D

P1476

Q44929883-7915CE79-E899-4CE7-8450-CBD2756EEEA3

P2093

Q44929883-0BD4C9F0-9CA7-4546-9C8C-7A5BBB116028

Q44929883-16CA8B60-1906-4805-BA4B-5EB58E81293A

Q44929883-23AA46AE-CA3B-4596-9979-B45E4C7FBF2A

Q44929883-330FEAB4-5F2C-429E-BD7B-D63077B1A2AB

Q44929883-67377769-7840-4125-B342-11DF942DB014

Q44929883-87D4A3B7-E398-49DB-885A-FFB98876C612

Q44929883-92B424A5-B92F-4A02-B9D7-875910284415

Q44929883-9654391C-1352-4C6A-A9CF-5DF6DBB80579

Q44929883-A7FBC7CD-B3C3-4CF6-9449-BD780E63C92D

Q44929883-BB148597-35F5-4FFF-867C-E6C30850E3D5

P304

Q44929883-6A2715D7-1C7C-4A29-862A-21971B41BB95

P31

Q44929883-7BB342C9-DDE6-4D6D-8A12-E89DCCC9C689

P356

Q44929883-38421189-FD9C-4F3D-A296-5E7972313EAA

P407

Q44929883-A430FF1D-149F-4DDA-A794-9B7FF267D41B

P433

Q44929883-EE4E18CC-DD47-4F72-B87A-BF8E2510CE76

P478

Q44929883-859CCBFE-F660-4071-956B-A04E042E2301

P50

Q44929883-21E457F0-A3BE-4364-A6D8-D01C657B171B

P577

Q44929883-AECB21FD-C336-4F69-82C7-A0F4FA577BE4

P5875

Q44929883-6383AE36-E9D9-4DBB-B06A-6EE52892C2C5

P698

Q44929883-08EBA5A1-0535-4954-9D48-1BA83A9570F2

P356

J.GASTRO.2004.03.018

P1433

Gastroenterology

P1476

Persistence of cccDNA during t ...... ing adefovir dipivoxil therapy

@en

P2093

Bettina Werle-Lapostolle

http://www.w3.org/2001/XMLSchema#string

Carol L Brosgart

http://www.w3.org/2001/XMLSchema#string

Christian Trepo

http://www.w3.org/2001/XMLSchema#string

Craig S Gibbs

http://www.w3.org/2001/XMLSchema#string

George Lau

http://www.w3.org/2001/XMLSchema#string

Jorg Petersen

http://www.w3.org/2001/XMLSchema#string

Karsten Wursthorn

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Scott Bowden

http://www.w3.org/2001/XMLSchema#string

Shan-Shan Chen

http://www.w3.org/2001/XMLSchema#string

P304

1750-1758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2004.03.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8519317

http://www.w3.org/2001/XMLSchema#string

P698

15188170

http://www.w3.org/2001/XMLSchema#string